The Manufacturers Life Insurance Company Has $1.58 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

The Manufacturers Life Insurance Company lowered its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 32.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 58,242 shares of the company's stock after selling 28,600 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.10% of Structure Therapeutics worth $1,580,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after buying an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at $40,000. Virtus ETF Advisers LLC increased its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the period. Finally, Assetmark Inc. raised its position in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after acquiring an additional 953 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Trading Up 1.0%

Shares of GPCR stock traded up $0.26 on Friday, reaching $24.69. The company had a trading volume of 322,359 shares, compared to its average volume of 929,498. The stock has a market cap of $1.42 billion, a PE ratio of -33.41 and a beta of -1.69. The company has a 50-day moving average of $21.09 and a 200-day moving average of $26.64. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on GPCR. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright lowered their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.